Top Page
Genscript Biotech
(OTC:1548)
Genscript Biotech (1548) vs. S&P 500 (SPY)
Genscript Biotech Business Overview & Revenue Model
Genscript Biotech Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.01B | 594.49M | 839.53M | 625.70M | 490.10M | 390.85M | Gross Profit |
| 541.49M | 272.13M | 409.55M | 304.08M | 282.52M | 255.89M | EBIT |
| -343.99M | 9.28M | -415.79M | -438.11M | -379.29M | -204.55M | EBITDA |
| -282.22M | 70.43M | -249.42M | -389.04M | -341.57M | -174.71M | Net Income Common Stockholders |
| -177.01M | 2.96B | -95.48M | -226.85M | -358.71M | -204.94M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 28.16M | 621.18M | 1.93B | 1.46B | 1.41B | 772.38M | Total Assets |
| 92.38M | 5.28B | 3.39B | 2.55B | 2.23B | 1.45B | Total Debt |
| 8.17M | 723.74M | 416.99M | 349.80M | 156.45M | 55.00M | Net Debt |
| -17.46M | 591.75M | -1.03B | -674.20M | -1.02B | -574.05M | Total Liabilities |
| 29.19M | 954.91M | 1.34B | 1.18B | 846.17M | 631.82M | Stockholders Equity |
| 61.71M | 4.32B | 1.39B | 1.01B | 1.05B | 901.71M |
| Cash Flow | Free Cash Flow | ||||
| -326.16M | -72.27M | -444.62M | -336.40M | -269.83M | -272.97M | Operating Cash Flow |
| -19.89M | 75.65M | -286.91M | -120.29M | -136.79M | -151.09M | Investing Cash Flow |
| -1.04B | -1.46B | -357.73M | -443.30M | -212.55M | -100.17M | Financing Cash Flow |
| 53.81M | 66.52M | 1.07B | 419.32M | 902.14M | 624.20M |
Genscript Biotech Technical Analysis
Genscript Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$142.14B | 30.34 | 16.09% | 1.42% | 19.29% | 31.42% | |
76 Outperform | $926.70B | 5.88 | 6.03% | 11.94% | 42.83% | ||
66 Neutral | $73.82B | 36.66 | 6.14% | 1.50% | 7.63% | -24.95% | |
56 Neutral | HK$3.13B | 17.43 | 4.47% | ― | -9.75% | ― | |
54 Neutral | HK$23.86B | 0.97 | -6.09% | ― | 41.41% | 7.26% | |
51 Neutral | $5.32B | 3.41 | -40.36% | 2.89% | 17.93% | 2.52% |
Genscript Biotech Corporate Events
Legend Biotech, an associate of Genscript Biotech, announced that CARVYKTI® generated approximately US$369 million in net trade sales for the quarter ended March 31, 2025. This announcement highlights the product’s strong market performance and its potential impact on the company’s financial health and industry standing.
Genscript Biotech Corporation has announced its 2025 Annual General Meeting, scheduled for May 29, 2025, in Nanjing, China. The meeting will address several key resolutions, including the adoption of the company’s audited financial statements, re-election of board members, and re-appointment of auditors. Additionally, the company seeks approval to allow its directors to issue new shares, a move that could potentially impact its capital structure and shareholder value.
Genscript Biotech Corporation announced a supplemental release regarding the financial results of its listed associate, Legend Biotech Corporation, for the fourth quarter and the year ended December 31, 2024. The announcement includes a Chinese translation of Legend Biotech’s press release, originally published in English, detailing financial performance and recent business highlights. Stakeholders are advised to consider investment risks carefully.
Genscript Biotech reported a significant increase in profit for the year ended December 31, 2024, primarily due to a gain from the deconsolidation of its cell therapy business, amounting to approximately US$3.2 billion. Despite a stable gross profit and a modest revenue growth of 6.1%, the adjusted net profit from continuing operations saw a slight increase of 2.9%, reflecting the company’s strategic adjustments and financial resilience.
Genscript Biotech Corporation announced the financial results of its associate, Legend Biotech Corporation, for the fourth quarter and year ended December 31, 2024. Legend Biotech, in which Genscript holds a 47.51% stake, filed its financial results with the SEC, highlighting recent business achievements. Shareholders are advised to consider investment risks when dealing with Genscript’s securities.
Genscript Biotech Corporation has announced the redesignation of Dr. Ross Allen Grossman from a non-executive Director to an independent non-executive Director, effective March 11, 2025. This change in the board’s composition reflects the company’s strategic focus on strengthening its governance structure, potentially enhancing its industry positioning and stakeholder confidence.
Genscript Biotech Corporation has announced the composition of its board of directors and the roles they will undertake. The board includes a mix of executive, non-executive, and independent non-executive directors, with various members serving on five established committees. This announcement highlights the company’s commitment to strong governance and strategic oversight, which is crucial for maintaining its competitive position in the biotechnology sector.
Genscript Biotech Corporation has announced a board meeting scheduled for March 11, 2025, to discuss and approve the company’s final results for the year ending December 31, 2024. The meeting will also consider the potential payment of a final dividend, highlighting the company’s ongoing financial management and potential shareholder returns.
Genscript Biotech Corporation has announced a substantial increase in net profit for the year ending December 31, 2024, compared to the previous year. The increase is attributed primarily to a one-time unrealized gain from the deconsolidation of Legend Biotech and a non-cash fair value loss related to Probio’s preferred shares. Additionally, the company’s non-cell therapy business remained stable, and future revenue growth is expected due to a new agreement involving LaNova sublicensing to Merck & Co., Inc. Shareholders and investors are advised to consult the company’s annual results announcement, expected by March 2025, for detailed financial information.
Genscript Biotech Corporation has established a Risk Management and ESG Committee to oversee the company’s risk management and environmental, social, and governance (ESG) strategies. This new committee will also have a Sub-committee focused on data security and geopolitical resilience, highlighting the company’s proactive approach to addressing emerging risks. Such a move underscores Genscript Biotech’s commitment to robust governance and strategic oversight, potentially enhancing its industry positioning by ensuring rigorous risk management and ESG compliance.
Genscript Biotech Corporation has announced the establishment of a sub-committee on data security and geopolitical resilience as part of its Risk Management and ESG Committee, effective February 5, 2025. This strategic move is aimed at bolstering the company’s oversight on critical risk areas including geopolitical, data security, cyber security, and cross-border intellectual property risks, which may enhance its operational robustness and market positioning.